IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-443-6209
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees56
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
IDEAYA Biosciences (NASDAQ:IDYA) Frequently Asked Questions
What is IDEAYA Biosciences' stock symbol?
IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."
How were IDEAYA Biosciences' earnings last quarter?
IDEAYA Biosciences (NASDAQ:IDYA) posted its quarterly earnings results on Monday, August, 12th. The company reported ($1.30) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.66. View IDEAYA Biosciences' Earnings History.
When is IDEAYA Biosciences' next earnings date?
What price target have analysts set for IDYA?
5 brokers have issued twelve-month price objectives for IDEAYA Biosciences' stock. Their forecasts range from $14.00 to $30.00. On average, they anticipate IDEAYA Biosciences' share price to reach $19.20 in the next year. This suggests a possible upside of 259.6% from the stock's current price. View Analyst Price Targets for IDEAYA Biosciences.
What is the consensus analysts' recommendation for IDEAYA Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEAYA Biosciences.
Has IDEAYA Biosciences been receiving favorable news coverage?
Media headlines about IDYA stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IDEAYA Biosciences earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for IDEAYA Biosciences.
Are investors shorting IDEAYA Biosciences?
IDEAYA Biosciences saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 25,400 shares, an increase of 9.5% from the August 15th total of 23,200 shares. Based on an average daily trading volume, of 24,700 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.3% of the shares of the stock are sold short. View IDEAYA Biosciences' Current Options Chain.
Who are some of IDEAYA Biosciences' key competitors?
Some companies that are related to IDEAYA Biosciences include Sinovac Biotech (SVA), Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH), Progenics Pharmaceuticals (PGNX), Evolus (EOLS), Avedro (AVDR), Crinetics Pharmaceuticals (CRNX), Synthorx (THOR), Stemline Therapeutics (STML), Beyondspring (BYSI), AMAG Pharmaceuticals (AMAG), Assembly Biosciences (ASMB), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS) and Verrica Pharmaceuticals (VRCA).
What other stocks do shareholders of IDEAYA Biosciences own?
Who are IDEAYA Biosciences' key executives?
IDEAYA Biosciences' management team includes the folowing people:
- Mr. Yujiro S. Hata, Co-Founder, CEO, Pres & Director (Age 45)
- Mr. Jeffrey Hager, Sr. VP, CTO, Head of Target Discovery & External Innovation (Age 55)
- Mr. Paul A. Stone, Sr. VP, Gen. Counsel & Head of Operations (Age 55)
- Mr. Michael P. Dillon, Sr. VP, Chief Scientific Officer & Head of Research (Age 52)
- Dr. Julie Hambleton, Sr. VP, Chief Medical Officer & Head of Devel. (Age 61)
When did IDEAYA Biosciences IPO?
(IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.
When does the company's lock-up period expire?
IDEAYA Biosciences' lock-up period expires on Tuesday, November 19th. IDEAYA Biosciences had issued 5,000,000 shares in its public offering on May 23rd. The total size of the offering was $50,000,000 based on an initial share price of $10.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
How do I buy shares of IDEAYA Biosciences?
Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IDEAYA Biosciences' stock price today?
One share of IDYA stock can currently be purchased for approximately $5.34.
How big of a company is IDEAYA Biosciences?
What is IDEAYA Biosciences' official website?
How can I contact IDEAYA Biosciences?
IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-6209 or via email at [email protected]
MarketBeat Community Rating for IDEAYA Biosciences (NASDAQ IDYA)
MarketBeat's community ratings are surveys of what our community members think about IDEAYA Biosciences and other stocks. Vote "Outperform" if you believe IDYA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDYA will underperform the S&P 500 over the long term. You may vote once every thirty days.
